1. Academic Validation
  2. Development of efficient one-pot three-component assembly of trityl olmesartan medoxomil

Development of efficient one-pot three-component assembly of trityl olmesartan medoxomil

  • Bioorg Med Chem. 2018 Aug 7;26(14):4348-4359. doi: 10.1016/j.bmc.2018.06.036.
Renata Toplak Časar 1 Zdenko Časar 2
Affiliations

Affiliations

  • 1 Lek Pharmaceuticals, d.d., Sandoz Development Center Slovenia, Verovškova ulica 57, 1526 Ljubljana, Slovenia.
  • 2 Lek Pharmaceuticals, d.d., Sandoz Development Center Slovenia, Verovškova ulica 57, 1526 Ljubljana, Slovenia; Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address: zdenko.casar@ffa.uni-lj.si.
Abstract

We have elaborated a one-pot three-component assembly of trityl olmesartan medoxomil starting from commercially available ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate, 5-(4'-(bromomethyl)-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole and 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one intermediates. The developed and optimized one-pot process provides 72-75% yield of trityl olmesartan medoxomil over three steps, which represents in average CA. 90% yield per synthetic step, on a 300 g scale. The process is conducted in simple fashion and provides highly pure trityl olmesartan medoxomil (up to 97.5% by HPLC), which can be easily converted to olmesartan medoxomil that fully complies with all ICH requirements. Furthermore, the described process significantly improves the primary process to trityl olmesartan medoxomil by drastic reduction of required unit operations and application of single reaction solvent through the reaction sequence. Moreover, the amount of used organic solvents was notably reduced. The developed process has provided solid bases for industrial production of trityl olmesartan medoxomil.

Keywords

Alkylation; Drugs; Ester hydrolysis; Heterocycles; Multicomponent reactions; Olmesartan; S(N)2 reaction.

Figures
Products